Identification
NameAluminium
Accession NumberDB01370  (DB11314)
TypeSmall Molecule
GroupsApproved
Description

A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.

Structure
Thumb
Synonyms
13Al
Al
Aluminio
Aluminium
Aluminium atom
Aluminum
External IDs C.I. 77000 / CI 77000 / E-173 / INS NO.173 / INS-173
Product Ingredients
IngredientUNIICASInChI KeyDetails
Aluminium phosphateF92V3S521O 7784-30-7ILRRQNADMUWWFW-UHFFFAOYSA-KDetails
Aluminum acetate80EHD8I43D 139-12-8WCOATMADISNSBV-UHFFFAOYSA-KDetails
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AstringentGel.008 mg/4mLTopicalCa Botana International2015-01-01Not applicableUs
Domeboro CoolingGel5 mg/mLTopicalMOBERG PHARMA NORTH AMERICA LLC2016-03-01Not applicableUs
GelfosGel61.9 g/100gOralBoryung Pharmaceutical Co., Ltd2015-04-182016-12-13Us
Gelfos MGel61.9 g/100gOralBoryung Pharmaceutical Co., Ltd2015-04-182016-12-13Us
Gelfos MGel61.9 g/100gOralBoryung Pharmaceutical Co., Ltd2016-02-282016-04-05Us
GelfoseGel61.9 g/100gOralBoryung Pharmaceutical Co., Ltd2015-03-082016-12-13Us
Gelfose MGel61.9 g/100gOralBoryung Pharmaceutical Co., Ltd2015-03-082016-12-13Us
Humco Aluminum Acetate (burrow)Liquid530 mg/mLTopicalHumco Holding Group. Inc.1998-03-25Not applicableUs
Pedi-boro Soak PaksPowder, for solution615 mg/1TopicalPedinol Pharmacal, Inc.2013-01-15Not applicableUs
Tricalm Extra StrengthSolution3 mg/mLTopicalCosmederm Bioscience2015-03-01Not applicableUs
Tricalm HydrogelGel2 mg/mLTopicalCosmederm Bioscience2013-11-01Not applicableUs
Zo Medical Surfatrol AstringentPowder4866 mg/4.866gTopicalZo Skin Health Inc2016-08-01Not applicableUs
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Buro-sol Otic SolutionSolutionAuricular (otic)Glaxosmithkline Inc1986-12-312015-01-05Canada
Gelfos MGelOralBoryung Pharmaceutical Co., Ltd2016-02-282016-12-13Us
Oti-solSolutionAuricular (otic)Jamp Pharma CorporationNot applicableNot applicableCanada
Star-otic SolutionSolutionAuricular (otic)Stellar Pharmacal Corp1992-12-311997-05-30Canada
Categories
UNIICPD4NFA903
CAS number7429-90-5
WeightAverage: 26.9815
Monoisotopic: 26.981538441
Chemical FormulaAl
InChI KeyXAGFODPZIPBFFR-UHFFFAOYSA-N
InChI
InChI=1S/Al
IUPAC Name
alumane
SMILES
[Al]
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

Aluminum Acetate is an astringent. An astrignent is a chemical that tends to shrink or constrict body tissues, usually locally after topical medicinal application. The shrinkage or constriction is through osmotic flow of water (or other fluids) away from the area where the astringent was applied. Astringent medicines cause shrinkage of mucous membranes or exposed tissues and are often used internally to check discharge of blood serum or mucous secretions. This can happen with a sore throat, hemorrhages, diarrhea, or with peptic ulcers. Externally applied astringents, which cause mild coagulation of skin proteins, dry, harden, and protect the skin. Acne sufferers are often advised to use astringents if they have oily skin. Astringents also help heal stretch marks and other scars. Mild astringent solutions are used in the relief of such minor skin irritations as those resulting from superficial cuts, allergies, insect bites, or fungal infections such as athlete's foot.

TargetKindPharmacological actionActionsOrganismUniProt ID
SerotransferrinProteinunknownNot AvailableHumanP02787 details
Sodium/potassium-transporting ATPase subunit alpha-1Proteinunknown
binder
HumanP05023 details
Kallikrein-1Proteinunknown
inhibitor
HumanP06870 details
Amyloid beta A4 proteinProteinunknownNot AvailableHumanP05067 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis Reference

Bela Czegledi, Mihaly Csovari, Miklos Erdelyi, Lajos Streker, Istvan Toth, Katalin Szabo nee Mogyorosi, Szilard Riederauer, Geza Szentgyorgyi, "Process for producing alumina and ferric oxide from aluminium carriers with high iron and silicon content." U.S. Patent US4366129, issued 1876.

US4366129
General ReferencesNot Available
External Links
ATC CodesA02AB03 — Aluminium phosphate
AHFS Codes
  • 20:12.12
  • 34:00.00
  • 52:28.00
  • 56:04.00
  • 84:04.92
  • 84:12.00
  • 84:92.00
  • 88:29.00*
  • 92:02.00*
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingPreventionCondylomata Acuminata1
1CompletedPreventionPlasmodium Falciparum Malaria1
2CompletedPreventionProphylaxis against postoperative nausea and vomiting1
2Not Yet RecruitingTreatmentMalaria caused by plasmodium vivax1
2Unknown StatusDiagnosticDermatitis, Contact1
3CompletedPreventionPlasmodium Infections1
3CompletedTreatmentFevers / Plasmodium Infections1
3CompletedTreatmentMalaria in Pregnancy1
3TerminatedTreatmentRadiation-induced Oesophagitis1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Malaria caused by Plasmodium falciparum1
4CompletedTreatmentMalaria caused by Plasmodium falciparum1
4CompletedTreatmentPlasmodium Infections1
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
4Unknown StatusTreatmentUncomplicated Falciparum Malaria1
Not AvailableCompletedTreatmentPlasmodium Infections1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
GelTopical.008 mg/4mL
SolutionAuricular (otic)
GelTopical5 mg/mL
GelOral
SuspensionOral
GelOral61.9 g/100g
LiquidTopical530 mg/mL
Powder, for solutionTopical615 mg/1
SolutionTopical3 mg/mL
GelTopical2 mg/mL
PowderTopical4866 mg/4.866g
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)2.375 g·cm −3Not Available
Predicted Properties
PropertyValueSource
logP1.45ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9838
Blood Brain Barrier+0.9733
Caco-2 permeable+0.7354
P-glycoprotein substrateNon-substrate0.881
P-glycoprotein inhibitor INon-inhibitor0.9787
P-glycoprotein inhibitor IINon-inhibitor0.9858
Renal organic cation transporterNon-inhibitor0.9108
CYP450 2C9 substrateNon-substrate0.8305
CYP450 2D6 substrateNon-substrate0.8255
CYP450 3A4 substrateNon-substrate0.8145
CYP450 1A2 substrateNon-inhibitor0.8813
CYP450 2C9 inhibitorNon-inhibitor0.9392
CYP450 2D6 inhibitorNon-inhibitor0.9716
CYP450 2C19 inhibitorNon-inhibitor0.9571
CYP450 3A4 inhibitorNon-inhibitor0.9855
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.882
Ames testNon AMES toxic0.9633
CarcinogenicityCarcinogens 0.664
BiodegradationReady biodegradable0.7326
Rat acute toxicity2.0135 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9547
hERG inhibition (predictor II)Non-inhibitor0.9746
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as homogeneous post-transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a post-transition metal atom.
KingdomChemical entities
Super ClassInorganic compounds
ClassHomogeneous metal compounds
Sub ClassHomogeneous post-transition metal compounds
Direct ParentHomogeneous post-transition metal compounds
Alternative ParentsNot Available
SubstituentsHomogeneous post-transition metal
Molecular FrameworkNot Available
External Descriptorselemental aluminium (CHEBI:33629 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transferrin receptor binding
Specific Function:
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and utilization. Serum transferrin may also have a further role in stimulating cell proliferation.
Gene Name:
TF
Uniprot ID:
P02787
Uniprot Name:
Serotransferrin
Molecular Weight:
77063.195 Da
References
  1. Nolte E, Beck E, Winklhofer C, Steinhausen C: Compartmental model for aluminium biokinetics. Hum Exp Toxicol. 2001 Feb;20(2):111-7. [PubMed:11327511 ]
  2. Nagaoka MH, Maitani T: Binding affinity of aluminium to human serum transferrin and effects of carbohydrate chain modification as studied by HPLC/high-resolution ICP-MS--speciation of aluminium in human serum. J Inorg Biochem. 2005 Sep;99(9):1887-94. [PubMed:16139893 ]
  3. Mizutani K, Mikami B, Aibara S, Hirose M: Structure of aluminium-bound ovotransferrin at 2.15 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1636-42. Epub 2005 Nov 19. [PubMed:16301797 ]
  4. Beardmore J, Rugg G, Exley C: A systems biology approach to the blood-aluminium problem: the application and testing of a computational model. J Inorg Biochem. 2007 Sep;101(9):1187-91. Epub 2007 Jun 12. [PubMed:17629565 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Uniprot Name:
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight:
112895.01 Da
References
  1. Menz RI, Walker JE, Leslie AG: Structure of bovine mitochondrial F(1)-ATPase with nucleotide bound to all three catalytic sites: implications for the mechanism of rotary catalysis. Cell. 2001 Aug 10;106(3):331-41. [PubMed:11509182 ]
  2. Silva VS, Goncalves PP: The inhibitory effect of aluminium on the (Na+/K+)ATPase activity of rat brain cortex synaptosomes. J Inorg Biochem. 2003 Sep 15;97(1):143-50. [PubMed:14507470 ]
  3. Amador FC, Santos MS, Oliveira CR: Lipid peroxidation and aluminium effects on the cholinergic system in nerve terminals. Neurotox Res. 2001 Jul;3(3):223-33. [PubMed:15111247 ]
  4. Kohila T, Parkkonen E, Tahti H: Evaluation of the effects of aluminium, ethanol and their combination on rat brain synaptosomal integral proteins in vitro and after 90-day oral exposure. Arch Toxicol. 2004 May;78(5):276-82. [PubMed:15254985 ]
  5. Kohila T, Tahti H: Effects of aluminium and lead on ATPase activity of knockout +/- mouse cerebral synaptosomes in vitro. Altern Lab Anim. 2004 Oct;32(4):361-7. [PubMed:15651920 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serine-type endopeptidase activity
Specific Function:
Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.
Gene Name:
KLK1
Uniprot ID:
P06870
Uniprot Name:
Kallikrein-1
Molecular Weight:
28889.425 Da
References
  1. De Sousa MO, Santoro MM, De Souza Figueiredo AF: The effect of cations on the amidase activity of human tissue kallikrein: 1-linear competitive inhibition by sodium, potassium, calcium and magnesium. 2-linear mixed inhibition by aluminium. J Enzyme Inhib Med Chem. 2004 Aug;19(4):317-25. [PubMed:15558947 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transition metal ion binding
Specific Function:
Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to ap...
Gene Name:
APP
Uniprot ID:
P05067
Uniprot Name:
Amyloid beta A4 protein
Molecular Weight:
86942.715 Da
References
  1. Banks WA, Niehoff ML, Drago D, Zatta P: Aluminum complexing enhances amyloid beta protein penetration of blood-brain barrier. Brain Res. 2006 Oct 20;1116(1):215-21. Epub 2006 Aug 30. [PubMed:16942756 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Uniprot Name:
Serum albumin
Molecular Weight:
69365.94 Da
References
  1. Zatta P, Dalla Via L, Di Noto V: Binding studies on aluminum(III)-albumin interaction. Arch Biochem Biophys. 2003 Sep 1;417(1):59-64. [PubMed:12921780 ]
Drug created on July 06, 2007 14:27 / Updated on August 02, 2017 16:32